Company news
Alpha Tau Medical Ltd (NASDAQ:DRTS) news
Alpha Tau Medical Ltd news releases on 6ix. Latest, Oct 5, 2026: Alpha Tau to Participate in October Investor Conferences
Press releases & updates
Alpha Tau to Participate in October Investor Conferences
October 5, 2026
Alpha Tau to Participate in September Investor Conferences
September 2, 2026
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
August 31, 2026
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
July 21, 2026
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
July 15, 2026
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
June 23, 2026
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
June 11, 2026
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 18, 2026
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
May 11, 2026
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
May 8, 2026
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
May 7, 2026
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
May 5, 2026
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
May 4, 2026
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
April 27, 2026
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
April 23, 2026
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
April 23, 2026
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
March 31, 2026
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
March 16, 2026
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
March 9, 2026
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
February 24, 2026
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
January 29, 2026
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer
January 20, 2026
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
January 6, 2026
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
January 5, 2026
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
December 18, 2025
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
December 9, 2025
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
December 4, 2025
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
December 2, 2025
Alpha Tau to Participate in December Investor Conferences
December 1, 2025
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 20, 2025
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
November 11, 2025
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
October 21, 2025
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
September 2, 2025
Alpha Tau to Participate in Five September Investor Conferences
August 27, 2025
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Alpha Tau to Present at Jefferies Global Healthcare Conference
May 28, 2025
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 19, 2025
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
May 12, 2025
Alpha Tau to Participate in May Investor Conferences
May 6, 2025
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
April 28, 2025
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
April 28, 2025
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
April 2, 2025
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
March 12, 2025
Alpha Tau to Participate in March Investor Conferences
February 27, 2025
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
February 24, 2025